Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

Autor: Aogi, Kenjiro, Watanabe, Kenichi, Kitada, Masahiro, Sangai, Takafumi, Ohtani, Shoichiro, Aruga, Tomoyuki, Kawaguchi, Hidetoshi, Fujisawa, Tomomi, Maeda, Shigeto, Morimoto, Takashi, Sato, Nobuaki, Takao, Shintaro, Morita, Satoshi, Masuda, Norikazu, Toi, Masakazu, Ohno, Shinji
Předmět:
Zdroj: International Journal of Clinical Oncology; Nov2022, Vol. 27 Issue 11, p1793-1793, 1p
Abstrakt: The correct version of names are: Takafumi Sangai and Hidetoshi Kawaguchi as given in this Correction. Correction to: International Journal of Clinical Oncology (2021) 26:1229-1236 https://doi.org... In the original publication, the name of fourth and seventh authors were incorrectly published as: Takashi Sangai and Hidetoshi Kawagichi. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz: